v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2026
segment
customer
product
item
Institution
Jun. 30, 2025
customer
Dec. 31, 2025
customer
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Number of commercialized products | product 1    
Number of operating segments | segment 1    
Number of reportable segments | segment 1    
Number of financial institutions | Institution 3    
Supplier concentration risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Number of suppliers | item 2    
Three Customers | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Number of customers | customer 3   3
Concentration risk percentage 100.00%   100.00%
Three Customers | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Number of customers | customer 3 3  
Concentration risk percentage 100.00% 100.00%  
Accredo Health Group, Inc | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration risk percentage 41.00%   45.00%
Accredo Health Group, Inc | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration risk percentage 37.00% 36.00%  
Caremark LLC | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration risk percentage 33.00%   36.00%
Caremark LLC | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration risk percentage 38.00% 38.00%  
PANTHERx Specialty Pharmacy LLC | Accounts Receivable | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration risk percentage 26.00%   19.00%
PANTHERx Specialty Pharmacy LLC | Product Revenues | Customer Concentration Risk      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration risk percentage 25.00% 26.00%